Literature DB >> 3663452

Cimetidine increases serum mebendazole concentrations. Implications for treatment of hepatic hydatid cysts.

A Bekhti1, J Pirotte.   

Abstract

In eight patients (five with peptic ulcer disease and three with hydatid cysts), the [14C]-aminopyrine breath test (ABT) and maximum serum concentration of mebendazole following a dose of 1.5 g of mebendazole three times daily were determined before and after treatment with cimetidine (400 mg three times daily for 30 days). Serum mebendazole concentrations were measured in blood samples taken 2 h after each drug intake. Cimetidine lowered the 14CO2 specific activity (SA) at 1 h (P less than 0.01) and increased the maximum serum concentration of mebendazole (P less than 0.01). A significant correlation was found between SA at 1 h and the highest concentration of mebendazole before (r = -0.71, P less than 0.05) and after (r = -0.82, P less than 0.05) cimetidine ingestion. Combined administration of cimetidine and mebendazole resulted in the complete resolution of previously unresponsive hydatid cysts.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3663452      PMCID: PMC1386263          DOI: 10.1111/j.1365-2125.1987.tb03186.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  8 in total

1.  A correlation between serum mebendazole concentrations and the aminopyrine breath test. Implications in the treatment of hydatid disease.

Authors:  A Bekhti; J Pirotte; R Woestenborghs
Journal:  Br J Clin Pharmacol       Date:  1986-02       Impact factor: 4.335

2.  Treatment of hydatid disease with high oral doses of mebendazole. Long-term follow-up of plasma mebendazole levels and drug interactions.

Authors:  P J Luder; B Siffert; F Witassek; F Meister; J Bircher
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 3.  Drug interactions with cimetidine.

Authors:  A Somogyi; R Gugler
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

4.  The pharmacokinetics of mebendazole and flubendazole in animals and man.

Authors:  M Michiels; R Hendriks; J Heykants; H van den Bossche
Journal:  Arch Int Pharmacodyn Ther       Date:  1982-04

Review 5.  Cimetidine-drug interactions.

Authors:  A J Sedman
Journal:  Am J Med       Date:  1984-01       Impact factor: 4.965

6.  Serum concentrations of mebendazole in patients with hydatid disease.

Authors:  A Bekhti
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1985-12

7.  Breath 14CO2 after intravenous administration of [14C]aminopyrine in liver diseases.

Authors:  S Pauwels; A P Geubel; C Dive; C Beckers
Journal:  Dig Dis Sci       Date:  1982-01       Impact factor: 3.199

8.  Radiological changes under effect of mebendazole on univesicular hydatid cysts in the liver and lung.

Authors:  A Bekhti; M Nizet
Journal:  Eur J Radiol       Date:  1986-05       Impact factor: 3.528

  8 in total
  13 in total

1.  Effect of ritonavir on the pharmacokinetics of the benzimidazoles albendazole and mebendazole: an interaction study in healthy volunteers.

Authors:  Natascia Corti; Antje Heck; Katharina Rentsch; Walter Zingg; Alexander Jetter; Bruno Stieger; Christiane Pauli-Magnus
Journal:  Eur J Clin Pharmacol       Date:  2009-06-27       Impact factor: 2.953

Review 2.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

Review 3.  Clinical pharmacokinetics of anthelmintic drugs.

Authors:  G Edwards; A M Breckenridge
Journal:  Clin Pharmacokinet       Date:  1988-08       Impact factor: 6.447

Review 4.  Diagnosis and treatment of human hydatidosis.

Authors:  H Wen; R R New; P S Craig
Journal:  Br J Clin Pharmacol       Date:  1993-06       Impact factor: 4.335

Review 5.  Anthelmintics. A comparative review of their clinical pharmacology.

Authors:  N de Silva; H Guyatt; D Bundy
Journal:  Drugs       Date:  1997-05       Impact factor: 9.546

6.  Enhancement of the drug susceptibility of a triclabendazole-resistant isolate of Fasciola hepatica using the metabolic inhibitor ketoconazole.

Authors:  Catherine Devine; Gerard P Brennan; Carlos E Lanusse; Luis I Alvarez; Alan Trudgett; Elizabeth Hoey; Ian Fairweather
Journal:  Parasitol Res       Date:  2010-05-30       Impact factor: 2.289

Review 7.  Clinical pharmacokinetics in the treatment of tropical diseases. Some applications and limitations.

Authors:  G Edwards; P A Winstanley; S A Ward
Journal:  Clin Pharmacokinet       Date:  1994-08       Impact factor: 6.447

Review 8.  A review of pharmacokinetic drug-drug interactions with the anthelmintic medications albendazole and mebendazole.

Authors:  Shane Ashley Pawluk; Craig Allan Roels; Kyle John Wilby; Mary H H Ensom
Journal:  Clin Pharmacokinet       Date:  2015-04       Impact factor: 5.577

Review 9.  Drug treatment of tropical parasitic infections: recent achievements and developments.

Authors:  I Stephenson; M Wiselka
Journal:  Drugs       Date:  2000-11       Impact factor: 11.431

10.  Repurposing Drugs in Oncology (ReDO)-mebendazole as an anti-cancer agent.

Authors:  Pan Pantziarka; Gauthier Bouche; Lydie Meheus; Vidula Sukhatme; Vikas P Sukhatme
Journal:  Ecancermedicalscience       Date:  2014-07-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.